SULT1A1
Basic information
Region (hg38): 16:28605196-28610044
Previous symbols: [ "STP", "STP1" ]
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SULT1A1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 2 | |||||
missense | 22 | 22 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 0 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 0 | |||||
non coding | 1 | |||||
Total | 0 | 0 | 23 | 2 | 1 |
Variants in SULT1A1
This is a list of pathogenic ClinVar variants found in the SULT1A1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
16-28605835-G-A | not specified | Uncertain significance (Dec 14, 2023) | ||
16-28605855-G-A | not specified | Uncertain significance (Jul 12, 2022) | ||
16-28605867-G-A | not specified | Uncertain significance (Dec 18, 2023) | ||
16-28605868-C-T | not specified | Uncertain significance (Dec 20, 2023) | ||
16-28605885-C-T | not specified | Uncertain significance (May 15, 2024) | ||
16-28605894-T-C | not specified | Uncertain significance (May 17, 2023) | ||
16-28605909-G-A | not specified | Uncertain significance (Oct 14, 2023) | ||
16-28606116-T-G | not specified | Uncertain significance (Jan 09, 2024) | ||
16-28606137-T-A | not specified | Uncertain significance (Jun 23, 2023) | ||
16-28606158-G-C | not specified | Uncertain significance (Jul 07, 2024) | ||
16-28606173-C-T | not specified | Uncertain significance (Nov 15, 2024) | ||
16-28606194-G-A | not specified | Uncertain significance (Dec 19, 2022) | ||
16-28606226-C-A | not specified | Uncertain significance (Dec 02, 2022) | ||
16-28606814-C-G | not specified | Uncertain significance (Oct 03, 2022) | ||
16-28606829-C-T | not specified | Uncertain significance (Oct 12, 2022) | ||
16-28606849-T-A | not specified | Uncertain significance (Sep 27, 2022) | ||
16-28606849-T-C | not specified | Uncertain significance (May 26, 2023) | ||
16-28606957-C-T | not specified | Uncertain significance (Oct 25, 2024) | ||
16-28607013-G-C | not specified | Uncertain significance (Apr 18, 2024) | ||
16-28607061-C-T | not specified | Uncertain significance (Dec 19, 2023) | ||
16-28607070-T-C | not specified | Uncertain significance (May 08, 2023) | ||
16-28608326-G-C | not specified | Uncertain significance (Aug 14, 2024) | ||
16-28608331-A-C | not specified | Uncertain significance (Nov 01, 2022) | ||
16-28608363-C-T | Likely benign (Apr 01, 2023) | |||
16-28608517-C-T | not specified | Uncertain significance (Sep 27, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SULT1A1 | protein_coding | protein_coding | ENST00000395609 | 7 | 18044 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.04e-11 | 0.0442 | 125578 | 6 | 123 | 125707 | 0.000513 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -1.19 | 219 | 175 | 1.25 | 0.0000105 | 1913 |
Missense in Polyphen | 77 | 59.01 | 1.3049 | 728 | ||
Synonymous | -3.39 | 106 | 69.9 | 1.52 | 0.00000451 | 538 |
Loss of Function | -0.0732 | 16 | 15.7 | 1.02 | 8.58e-7 | 160 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00198 | 0.00198 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00163 | 0.00163 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000353 | 0.000325 |
Middle Eastern | 0.00163 | 0.00163 |
South Asian | 0.000261 | 0.000261 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of catecholamines, phenolic drugs and neurotransmitters. Has also estrogen sulfotransferase activity. responsible for the sulfonation and activation of minoxidil. Is Mediates the metabolic activation of carcinogenic N- hydroxyarylamines to DNA binding products and could so participate as modulating factor of cancer risk. {ECO:0000269|PubMed:12471039, ECO:0000269|PubMed:16221673}.;
- Pathway
- Chemical carcinogenesis - Homo sapiens (human);Aromatase Inhibitor Pathway (Multiple Tissues), Pharmacodynamics;Estrogen Metabolism Pathway;Tamoxifen Pathway, Pharmacokinetics;Pathway_PA165986194 -need delete;Acetaminophen Pathway, Pharmacokinetics;Sulfate/Sulfite Metabolism;Sulfite oxidase deficiency;Tamoxifen Action Pathway;Lamivudine Metabolism Pathway;Acetaminophen Metabolism Pathway;Tamoxifen Metabolism Pathway;Constitutive Androstane Receptor Pathway;Nuclear Receptors Meta-Pathway;Melatonin metabolism and effects;Liver steatosis AOP;Tamoxifen metabolism;Sulfation Biotransformation Reaction;Arylamine metabolism;Estrogen metabolism;Metapathway biotransformation Phase I and II;Vitamin A and Carotenoid Metabolism;Phase II - Conjugation of compounds;Biological oxidations;Metabolism;Cytosolic sulfonation of small molecules;thyroid hormone metabolism II (via conjugation and/or degradation);serotonin degradation;superpathway of tryptophan utilization;melatonin degradation I;superpathway of melatonin degradation
(Consensus)
Recessive Scores
- pRec
- 0.407
Intolerance Scores
- loftool
- 0.205
- rvis_EVS
- -0.16
- rvis_percentile_EVS
- 42.16
Haploinsufficiency Scores
- pHI
- 0.0997
- hipred
- N
- hipred_score
- 0.172
- ghis
- 0.462
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.969
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sult1a1
- Phenotype
- liver/biliary system phenotype; homeostasis/metabolism phenotype; cellular phenotype;
Gene ontology
- Biological process
- ethanol catabolic process;catecholamine metabolic process;xenobiotic metabolic process;estrogen metabolic process;amine metabolic process;flavonoid metabolic process;3'-phosphoadenosine 5'-phosphosulfate metabolic process;sulfation
- Cellular component
- cytosol
- Molecular function
- aryl sulfotransferase activity;protein binding;sulfotransferase activity;flavonol 3-sulfotransferase activity;steroid sulfotransferase activity